Partner Smart with End-to-End CDMO
What if you could rely on one partner to source APIs, formulate and develop drug products, and manufacture at clinical and commercial scale? Rather than too many links in your supply chain, an end-to-end CDMO reduces layers of administration, gaps in knowledge, time, cost, and risk. Download our white paper to learn the five “must ask” questions to find the right CDMO.
Advanced LC-MS Technology for Enhanced HCP Detection in Complex Biotherapeutics
February 26th 2025The identification, characterization, and quantitation of host cell protein (HCP) impurities are a critical challenge in the biopharmaceutical industry. Advanced LC-MS techniques can be integrated into manufacturing workflows to mitigate risks and ensure higher product quality and improved patient safety.
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERY
February 14th 2025Obesity is a significant global health challenge that requires lifestyle changes and effective pharmacological treatments to overcome. Human glucagon-like peptide 1 (GLP-1) analogs, also called incretin mimetics, have emerged as a promising obesity treatment option. Additionally, oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering greater patient comfort and adherence to expand the therapeutic market.
